Modifiedpriority healthPolicy N/A

Enuresis therapy (pediatric nocturnal enuresis)

This policy governs evaluation and treatment of nocturnal enuresis in pediatric patients, specifying medically necessary interventions (e.g., medical evaluation, enuresis alarms, desmopressin) and identifying non-covered services. It applies to Priority Health products per member benefits.

Policy Summary

Payerpriority health

PolicyEnuresis therapy (pediatric nocturnal enuresis)

Policy CodePolicy N/A

Change TypeMaterial updates to non-covered servicesrevised alarm therapy duration

Effective DateMar 1, 2026

Next Review DateN/A

Key ActionDocument a medical evaluation to rule out organic disease before initiating enuresis therapy.

SourceLink

POLICY UPDATE CHANGES

Additional non-covered services were added.

Updated alarm therapy treatment time to latest literature.

New Medical/Professional Society Guidelines section was added.

New Policy Scope Section was added.

New Government Regulations section listing applicable CMS NCDs or LCDs was added.

New FDA/Regulatory section was added.

Added updated references.

3core covered interventions listed

9explicit non-covered services listed

2ICD-10 codes listed

1CPT/HCPCS code listed

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

12-16typical alarm therapy duration (weeks)

Coverage Criteria for Enuresis Therapy

Medically necessary enuresis therapy

Covered when ALL of the following are met:

Medically necessary enuresis therapy: (1) Medical evaluation to rule out organic disease is documented (see supporting ICD-10 codes N39.44, F98.0).

Evaluation per ICCS guidance; exclude warning signs before invasive testing.

Medically necessary enuresis therapy: (2) Enuresis alarm/urine alarm is prescribed and provided (covered at the DME benefit level).

Alarm should be used nightly; continue ≥3 months if early improvement seen; discontinue when 14 consecutive dry nights achieved (typically 12–16 weeks).

Medically necessary enuresis therapy: (3) Prescription pharmacologic therapy (e.g., desmopressin) when indicated is prescribed and documented.

Desmopressin response expected within 1–2 weeks; continue for 3 months if improvement noted; follow recommended dosing/holidays and tapering per guidelines.

This policy governs coverage for pediatric nocturnal enuresis treatment. Covered program components include a documented medical evaluation to rule out organic disease, provision of an enuresis alarm/urine alarm (covered at the DME benefit level), and prescription drugspersonal or household items (for example, diapers and bedding).

The document cites multiple complementary and device-based therapies (parasacral transcutaneous electrical nerve stimulation, acupuncture/laser acupuncture, Tuina massage, and AI-enabled wearable systems) and references randomized trials and systematic reviews for these modalities, but the referenced background and evidence sections do not present explicit coverage exclusion language for those specific items beyond their listing in the evidence discussion.

Therapies and device types discussed in the policy and supporting literature include: electrical stimulation therapies (e.g., TENS, PTNS, parasacral transcutaneous electrical nerve stimulation), acupuncture (including laser acupuncture), Tuina (massage) therapy, AI-enabled wearable devices and other miniaturized mechatronic systems designed to detect bladder fullness, and additional complementary treatments such as hypnotherapy, psychotherapy, and chiropractic care.

Within the background and evidence sections the policy summarizes trials and reviews of PTENS, acupuncture, Tuina, and AI/wearable technologies, but these sections do not contain standalone determinations labeled as not medically necessary; the evidence discussion notes limited or low-quality data and recommends further research.

Coding and Billing

Covered HCPCS/CPT CodesHCPCSCovered

S8270

Enuresis alarm, using auditory buzzer and/or vibration device

Supporting ICD-10 CodesICD-10

N39.44	Nocturnal enuresis
F98.0	Enuresis not due to a substance or known physiological condition

Coding statementmixed

AMA CPT Copyright Statement

CPT codes and descriptions are copyrighted by the American Medical Association.

Provider Actions, Authorization & Documentation

Prior Authorization

Prior Authorization May Be Required

Prior authorization may be required for certain drugs, devices, services, and procedures. When prior authorization is required, providers must submit documentation demonstrating medical necessity per Priority Health requirements. Refer to the Priority Health Provider Manual for submission instructions and payer-specific forms.

See Priority Health Provider Manual for PA submission details
Individual case review required for investigational/promising therapies

Note

Authorization / Denial Triggers Not Explicit

There are no explicit authorization or denial triggers listed in this policy. The policy describes covered and non-covered services and cites evidence for various therapies, but it does not provide a definitive list of automatic approval or denial conditions. Providers should not assume automatic coverage based on this document alone and should submit requests for review when coverage is uncertain.

No automatic authorization/denial rules specified in this policy

Background and Rationale

Background: Nocturnal enuresis is defined as urinary incontinence during sleep in children aged five years or older. Management begins with a medical evaluation to exclude organic causes; routine invasive testing is not required unless alarm features are present. For monosymptomatic nocturnal enuresis, clinical guidelines identify enuresis alarms and desmopressin as first-line treatments. Alarm therapy should be used nightly and continued according to guideline-recommended durations (with improvement typically assessed over several weeks and discontinued once 14 consecutive dry nights are achieved; typical time to that outcome is about 12–16 weeks), and medication therapy is covered under the prescription drug benefit when indicated.

Definitions and Key Terms

Nocturnal enuresis — definition and ICD-10 examples

DefinitionUrinary incontinence during sleep in a child age ≥5 years; considered abnormal in children ≥5 and active therapy recommended from age 6.

Common associated conditionsConstipation, obstructive sleep apnea, diabetes mellitus, diabetes insipidus, chronic kidney disease, psychiatric disorders.

ICD-10 examples that may support medical necessityN39.44 (Nocturnal enuresis); F98.0 (Enuresis not due to a substance or known physiological condition).

Monosymptomatic nocturnal enuresis — distinguishing features

DefinitionEnuresis occurring in children without any other lower urinary tract symptoms and without a history of bladder dysfunction (monosymptomatic).

First-line therapies

Policy Summary

Payerpriority health

PolicyEnuresis therapy (pediatric nocturnal enuresis)

Policy CodePolicy N/A

Change TypeMaterial updates to non-covered servicesrevised alarm therapy duration

Effective DateMar 1, 2026

Next Review DateN/A

Key ActionDocument a medical evaluation to rule out organic disease before initiating enuresis therapy.

SourceLink

On This Page

Submit requests for individual case review when coverage is uncertain

Documentation Required

Medical Evaluation Documentation Required

Document a complete medical evaluation to rule out organic disease prior to initiating enuresis-specific therapies. Documentation should include relevant diagnostic assessment, history of lower urinary tract symptoms, evaluation for associated conditions (e.g., constipation, obstructive sleep apnea, diabetes mellitus/insipidus, chronic kidney disease, psychiatric disorders), and applicable diagnosis codes.

Record assessment to rule out organic disease and monosymptomatic vs non-monosymptomatic enuresis
Include relevant diagnosis codes and clinical findings in the medical record

Note

First-line Therapy Sequence

For monosymptomatic nocturnal enuresis in children (age ≥5 years, active therapy commonly from age 6), initial treatment should follow established first-line options: enuresis (wetting) alarms and desmopressin. Alarm therapy should be used nightly and continued at least three months if early improvement is seen, or until 14 consecutive dry nights are achieved (typically 12–16 weeks). Desmopressin response is expected within 1–2 weeks; continue for three months if improvement occurs and consider periodic treatment holds to reassess need.

Enuresis alarms and desmopressin are first-line therapies for monosymptomatic nocturnal enuresis
Alarm therapy: nightly use, continue ≥3 months if improving, stop after 14 consecutive dry nights when achieved
Desmopressin: evaluate response in 1–2 weeks; continue up to 3 months if improvement; consider one-week hold every 3 months if used daily

Denial Risk

Denial Risk for Investigational / Unproven Therapies

Experimental, investigational, or unproven treatments (for example: electrical stimulation therapies, acupuncture, tuina massage, AI wearable devices, hypnotherapy, psychotherapy, chiropractic care) are listed as non-covered in this policy or require individual case review for consideration. Requests for exception or coverage of investigational therapies require prior plan approval and review by a Priority Health medical director or clinical pharmacist.

Non-covered / investigational therapies may be considered only via individual case review with prior approval
Coverage determinations for investigational treatments are made by a medical director or clinical pharmacist

Enuresis alarms and desmopressin are established first-line treatments for monosymptomatic nocturnal enuresis (Level 1, Grade A recommendation for alarms).

Treatment expectationsAlarm therapy should be used nightly and continued at least three months if early improvement is seen; stop when 14 consecutive dry nights are achieved (typically 12–16 weeks).

PTENS — definition and evidence note

DefinitionParasacral transcutaneous electrical nerve stimulation (PTENS) — noninvasive electrical nerve stimulation applied to the parasacral region for treatment of pediatric enuresis.

Evidence baseReferenced via a systematic review and meta-analysis of randomized controlled trials (Toale et al., Neurourol Urodyn. 2022).

Context in policyListed among complementary/device therapies discussed in recent reviews; evidence cited but policy classifies electrical stimulation therapies (e.g., PTENS, PTNS) as non-covered or lacking sufficient high-quality evidence.

AI-enabled wearable devices — definition and recent evidence

DefinitionMiniaturized smart mechatronic and wearable systems incorporating sensors and AI for monitoring and potentially managing nocturnal enuresis (e.g., devices to detect bladder fullness or trigger alarms).

Recent evidence topicsPublished engineering and pediatrics studies describe AI-enabled miniaturised systems and wearable-based integrated monitoring for in‑home analysis of nocturnal enuresis (Kuru et al. 2023; Lee et al. 2024; Cammisa et al. 2025).

Policy positionAI wearable devices are discussed in the literature but are listed among complementary/device therapies that the policy identifies as non-covered or lacking sufficient high‑quality evidence.